Ticker Details
Verastem, Inc. Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.
IPO Date:	February 1, 2012
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$446.65M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.17 | 3.40%
Avg Daily Range (30 D):	$0.23 | 3.45%
Avg Daily Range (90 D):	$0.26 | 3.35%

Institutional Daily Volume
Avg Daily Volume:	.74M
Avg Daily Volume (30 D):	1.5M
Avg Daily Volume (90 D):	1.88M

Trade Size
Avg Trade Size (Sh.):	148
Avg Trade Size (Sh.) (30 D):	97
Avg Trade Size (Sh.) (90 D):	110

Institutional Trades
Total Institutional Trades:	835
Avg Institutional Trade:	$1.65M
Avg Institutional Trade (30 D):	$1.13M
Avg Institutional Trade (90 D):	$1.31M
Avg Institutional Trade Volume:	.13M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.83M
Avg Closing Trade (30 D):	$1.12M
Avg Closing Trade (90 D):	$1.41M
Avg Closing Volume:	133.13K

News

Nov 12, 2025 @ 6:00 PM KRAS Inhibitors Market to Witness Explosive Growth... Source: Delveinsight

Jul 23, 2025 @ 1:26 PM High‑Growth Oncology Market Projected For U... Source: Prnewswire

Mar 8, 2025 @ 12:33 PM Why the Global Cancer Market Could Surpass $900 Bi... Source: Prnewswire

Jul 24, 2024 @ 9:27 AM Why Enphase Energy Shares Are Trading Higher; Here... Source: Avi Kapoor

Jul 10, 2024 @ 6:51 PM Verastem, Inc. Investors: Company Investigated by ... Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-4.28	$-1.35	$-.39
Diluted EPS	$-4.28	$-1.35	$-.62
Revenue	$13.38M	$11.24M	$2.14M
Gross Profit
Net Income / Loss	$-241.11M	$-98.52M	$-25.93M
Operating Income / Loss	$-160.24M	$-40.72M	$-43.76M
Cost of Revenue
Net Cash Flow	$24.53M	$48.89M	$M
PE Ratio

Splits
Jun 01, 2023	1:12